agrile...NEPT-Tetra Bio Pharma - Genacol >>commercializationTetrabiopharma was working with NEPT, recall the post I made months ago about the hemmorhoid cream that was in late stage approval process? Now also recall when I became very upset about NEPT not having a cannabis R&D license from Health Canada and I emailed Mario at NEPT investor relations and recall his phone mail ansswer to me was that NEPT uses approved outside sources for that type of work....one could safely point to Tetra Bio Pharma as the one witih proper licensing to conduct human trials.
Hope this below helps to connect the dots between NEPT-Tetra Bio Pharma-Genacol Canada
Press Release 1 linking NEPT to Tetra Bio Pharma for pain relief and inflammatioin
LAVAL, QUBEC--(Marketwired - Feb. 12, 2018) - Tetra Bio-Pharma Inc. ("Tetra") (TSX VENTURE:TBP)(OTCQB:TBPMF) and Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ:NEPT)(TSX:NEPT) today announced that they entered into an agreement for the co-development, commercialization and marketing of purified cannabinoid oil-based products to address pain and inflammation relief applications for the natural health products and pet veterinary markets. https://www.globenewswire.com/news-release/2018/02/12/1482656/0/en/Neptune-and-Tetra-Bio-Pharma-Enter-Co-Development-Agreement-for-Purified-Cannabinoid-Oil-Based-Products-targeting-Pain-and-Inflammation.html Press Release 2 linking Tetra Bio Pharma to Genacol for commercialization of CBD based product for pain relief and inflammation
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Genacol will be responsible for the promotion and sales of these products throughout their network in Canada. According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol. Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network. “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.”
https://tetrabiopharma.com/2018/08/genacol-canada-corporation-and-tetra-bio-pharma-team-up-to-bring-innovative-cannabinoid-treatments-to-self-care-market-in-canada/